2:07 PM
 | 
Dec 06, 2017
 |  BC Extra  |  Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations.

Ayala SVP...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >